Immunome Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evaluating Immunome: Insights From 4 Financial Analysts - Immunome (NASDAQ:IMNM)

Evaluating Immunome: Insights From 4 Financial Analysts - Immunome (NASDAQ:IMNM)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Health careImmunome incAnalyst ratingsCapitalization analysis

Keros Therapeutics Appoints Jean-Jacques Bienaimé To Its Board Of Directors

Keros Therapeutics Appoints Jean-Jacques Bienaimé To Its Board Of Directors
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

France generalJasbir seehraJean jacques bienaimePoulenc rorer pharmaceuticalsGenentech incBiomarin pharmaceutical incGenencor incKeros therapeutics incCompany nasdaqIncyte corporationWharton schoolUniversity of pennsylvaniaBusiness developmentImmunome incSangstat medical corporationChief executive officer jasbir seehra

Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying - Astrotech (NASDAQ:ASTC)

United statesDanh wilksMatthew wilksRaymond jamesFrankm svobodaClayb siegallWilma burdisThomas wiley wilkinsonLance turnerProfrac holdingGl coAstrotech corpGlobe life incProfrac holding corpImmunome incAstrotech corporation

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related.

Clay siegallJack higginsAtreca incImmunome incChief scientificChief executive officerExchange actPrivate securities litigation reform actAnnual reportQuarterly report

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer,.

United statesClay siegallYale universityBoston consulting groupImmunome incSecurities exchangeGeorgia institute of technologyMax rosettChief financial officerExecutive vice presidentInterim chief financial officerChief executiveActing chief operating officerResearch bridge partnersComputer scienceGeorgia institute